Transplantační medicína

Dupilumab's* efficacy and safety in severe CRSwNP was established in the LIBERTY NP SINUS-24 and SINUS-52 randomized, double-blind, placebo-controlled phase 3 trials, and is reflected in the approved SmPC.^1,2

As real-world context to this robust RCT evidence, the observational RELIBIO study** provides additional insight into clinical effectiveness, treatment response, and switching patterns among 360 patients with severe CRSwNP treated with dupilumab (n=53), omalizumab (n=65) and mepolizumab (n=242) in routine Belgian clinical practice.³

Dupilumab's* efficacy and safety in severe CRSwNP was established in the LIBERTY NP SINUS-24 and SINUS-52 randomized, double-blind, placebo-controlled phase 3 trials, and is reflected in the approved SmPC.^1,2

As real-world context to this robust RCT evidence, the observational RELIBIO study** provides additional insight into clinical effectiveness, treatment response, and switching patterns among 360 patients with severe CRSwNP treated with dupilumab (n=53), omalizumab (n=65) and mepolizumab (n=242) in routine Belgian clinical practice.³

Dupilumab's* efficacy and safety in severe CRSwNP was established in the LIBERTY NP SINUS-24 and SINUS-52 randomized, double-blind, placebo-controlled phase 3 trials, and is reflected in the approved SmPC.^1,2

As real-world context to this robust RCT evidence, the observational RELIBIO study** provides additional insight into clinical effectiveness, treatment response, and switching patterns among 360 patients with severe CRSwNP treated with dupilumab (n=53), omalizumab (n=65) and mepolizumab (n=242) in routine Belgian clinical practice.³

Here’s a podcast starring Dr. Alice Cheng as she reviews the evidence behind second-generation basal insulins and their role in delivering safe, flexible, and proven glycemic control across a wide spectrum of Diabetes populations, including older adults and those with renal impairment and associated co-morbidities.

Leading international health authorities and their affiliated medical associations now recommend age-appropriate influenza vaccination, reflecting a global consensus shaped by robust clinical evidence.

High-Dose Influenza vaccine (HD-IIV) is recommended by different Gulf Health authorities and medical associations for their older adults co-morbid populations

Health authorities and leading medical societies—from the Gulf region to beyond—now preferentially recommend high-dose influenza vaccination for older adults, driven by robust clinical evidence demonstrating superior protection against influenza-related complications

Cette vidéo met en lumière l'ancienneté, la robustesse et la richesse du programme clinique de Plavix^® à travers six études emblématiques ayant marqué l'histoire de la prévention cardiovasculaire. Découvrez les résultats qui ont contribué à façonner la pratique clinique et à renforcer la confiance des professionnels de santé dans la prise en charge du risque athérothrombotique.

Insulina i niektóre leki mogą obniżać glikemię nawet bez posiłku. Dowiedz się, kiedy ryzyko hipoglikemii rośnie i jak bezpiecznie postępować.

Prof. Dr. Ortiz, Fabry hastalığında tedavi dozunun klinik sonuçlar üzerindeki etkisini video röportajında açıklıyor.